- Home
- IMRN vs NRXP Comparison
IMRN vs NRXP Comparison
Compare IMRN & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- NRXP
- Stock Information
- Founded
- IMRN 1994
- NRXP 2015
- Country
- IMRN Australia
- NRXP United States
- Employees
- IMRN N/A
- NRXP N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- NRXP Health Care
- Exchange
- IMRN Nasdaq
- NRXP Nasdaq
- Market Cap
- IMRN 9.2M
- NRXP 58.5M
- IPO Year
- IMRN N/A
- NRXP N/A
- Fundamental
- Price
- IMRN $2.18
- NRXP $3.17
- Analyst Decision
- IMRN
- NRXP Strong Buy
- Analyst Count
- IMRN 0
- NRXP 5
- Target Price
- IMRN N/A
- NRXP $31.40
- AVG Volume (30 Days)
- IMRN 77.5K
- NRXP 409.4K
- Earning Date
- IMRN 08-29-2025
- NRXP 11-13-2025
- Dividend Yield
- IMRN N/A
- NRXP N/A
- EPS Growth
- IMRN N/A
- NRXP N/A
- EPS
- IMRN N/A
- NRXP N/A
- Revenue
- IMRN $4,777,422.00
- NRXP N/A
- Revenue This Year
- IMRN N/A
- NRXP N/A
- Revenue Next Year
- IMRN N/A
- NRXP $395.09
- P/E Ratio
- IMRN N/A
- NRXP N/A
- Revenue Growth
- IMRN 48.63
- NRXP N/A
- 52 Week Low
- IMRN $1.50
- NRXP $1.10
- 52 Week High
- IMRN $2.48
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- IMRN 62.79
- NRXP 50.93
- Support Level
- IMRN $1.98
- NRXP $2.95
- Resistance Level
- IMRN $2.30
- NRXP $3.84
- Average True Range (ATR)
- IMRN 0.11
- NRXP 0.25
- MACD
- IMRN -0.00
- NRXP -0.04
- Stochastic Oscillator
- IMRN 62.79
- NRXP 30.76
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.